Naproxen etemesil
Alternative Names: LT-NS001; MX-1094Latest Information Update: 19 Jun 2015
Price :
$50 *
At a glance
- Originator Medinox
- Developer Logical Therapeutics
- Class Analgesics; Antipyretics; Antirheumatics; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 26 May 2010 Naproxen etemesil is available for licensing worldwide (http://www.logicaltx.com)
- 26 Apr 2010 Phase-II clinical trials in Osteoarthritis in United Kingdom (PO)
- 26 Apr 2010 Phase-II clinical trials in Osteoarthritis in USA (PO)